Clinical Trials Logo

Erythrodermic Psoriasis clinical trials

View clinical trials related to Erythrodermic Psoriasis.

Filter by:
  • None
  • Page 1

NCT ID: NCT06323356 Recruiting - Clinical trials for Generalized Pustular Psoriasis

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Start date: March 19, 2024
Phase: Phase 3
Study type: Interventional

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

NCT ID: NCT06295692 Recruiting - Clinical trials for Generalized Pustular Psoriasis

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Start date: February 9, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).

NCT ID: NCT03942042 Completed - Clinical trials for Generalized Pustular Psoriasis

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Start date: July 5, 2019
Phase: Phase 4
Study type: Interventional

The reason for this study is to see if the study drug ixekizumab is safe and effective in participants with generalized pustular psoriasis and erythrodermic psoriasis.

NCT ID: NCT03885089 Completed - Psoriasis Vulgaris Clinical Trials

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Start date: October 21, 2019
Phase:
Study type: Observational

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under actual status of use.